Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
- 22 January 2025 - 1 mins read
This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.
22 January 2025
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
22 January 2025
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
22 January 2025
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
22 January 2025
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
22 January 2025
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
22 January 2025
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
22 January 2025
1 mins read
Dysport® Adult Lower Limb Spasticity Study
22 January 2025
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
22 January 2025
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
22 January 2025
1 mins read